Thomas Miller

Thomas Miller serves as CSO of Tiaki Therapeutics. He is a seasoned drug hunter with a track-record of identifying and advancing drug candidates into clinical development, including nine molecules evaluated in clinical trials and the successful approval of Zolinza®. Most recently, Dr. Miller held the role of head of discovery chemistry at Shire, where he built and oversaw all key aspects of small molecule drug discovery for rare diseases and other unmet medical needs. Prior to that he held positions of increasing responsibility during a 10-year tenure at Merck, where he led drug discovery teams, development teams, and provided strategic leadership and oversight to licensing, collaboration and global business initiatives. Prior to Merck, he joined Aton Pharma as a founding employee, where he served as the head of chemistry and made substantive contributions to the company’s valuation that supported its successful acquisition by Merck and the approval of Zolinza®. He has also served as a member of the Scientific Advisory Board at UBS AG, where he provided science and technology advising to the Global Equities Division of one of Wall Street’s largest investment banks.

Dr. Miller holds a Bachelor’s degree in chemistry from Indiana University SE, a Ph.D. in chemistry from the University of Virginia and was a postdoctoral fellow at Columbia University. He has contributed to more than 100 scientific publications and patents.